To amend the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts relating to dietary supplements.
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™H.R. 8123 is a bill introduced in the 118th Congress aimed at amending the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts specifically related to dietary supplements. The bill seeks to define and prohibit certain actions concerning dietary supplements to enhance regulatory oversight and consumer protection. As of the latest update, the bill was referred to the House Subcommittee on Health but has since failed or expired without further legislative action. No full text or detailed summary is publicly available, limiting the ability to provide a detailed analysis of the specific provisions.
H.R. 8123 intended to strengthen regulations on dietary supplements by defining new prohibited acts but did not advance beyond subcommittee referral and ultimately expired.
- The bill proposes amendments to the Federal Food, Drug, and Cosmetic Act focused on dietary supplements.
- It aims to establish new prohibited acts related to dietary supplements to improve regulatory clarity.
- The bill was referred to the House Subcommittee on Health on April 26, 2024, but did not progress further and expired.
['Consumers of dietary supplements who may gain increased protections.', 'Regulatory agencies such as the Food and Drug Administration (FDA) tasked with oversight of dietary supplements.', 'Manufacturers and distributors of dietary supplements who would have clearer regulatory guidelines.']
['Lack of publicly available full bill text limits understanding of specific regulatory changes and enforcement mechanisms.', 'Potential increased regulatory compliance costs for dietary supplement manufacturers and distributors.', 'Unclear oversight and enforcement provisions could affect implementation effectiveness.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not advance beyond this stage and is classified as failed or expired. The legislative context involves ongoing efforts to regulate dietary supplements under the Federal Food, Drug, and Cosmetic Act, a key statute governing food and drug safety in the United States.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential for increased regulatory scrutiny on dietary supplement industry practices.', 'Possible shifts in market behavior by dietary supplement manufacturers to comply with new prohibitions.', 'Enhanced consumer confidence in dietary supplement safety if regulatory enforcement is effective.']
Transparency is limited by the absence of the full bill text and official summary, constraining comprehensive analysis. Monitoring the bill's referral to the Subcommittee on Health and its failure to advance highlights the importance of tracking legislative progress and access to complete legislative documents for public oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.